BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Velzatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Velzatinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07862114-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Velzatinib: Phase 1 readout est. (NCT07862114)
DESCRIPTION:Velzatinib\, phase 1.\nStudy: A Study to Investigate the Effect
  of Omeprazole and Cyclosporine on Velzatinib in Healthy Participants\nEst
 imated primary completion: 12 January 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/velzatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07862114
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867171-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20270909
DTEND;VALUE=DATE:20270910
SUMMARY:Velzatinib: Phase 1 readout est. (NCT07867171)
DESCRIPTION:Velzatinib\, phase 1.\nStudy: A Study to Investigate the Effect
 s of Moderate or Severe Renal Impairment (RI) on Velzatinib\nEstimated pri
 mary completion: 9 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/velzatinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07867171
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689201-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:Velzatinib: Phase 2 readout est. (NCT07689201)
DESCRIPTION:Velzatinib\, phase 2.\nStudy: A Study of Velzatinib in Particip
 ants With Metastatic and/or Unresectable GIST After Imatinib\, Sunitinib\,
  Regorafenib\, and Pimitespib\nEstimated primary completion: 29 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/velzatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07689201
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859735-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20280425
DTEND;VALUE=DATE:20280426
SUMMARY:Velzatinib: Phase 1 readout est. (NCT07859735)
DESCRIPTION:Velzatinib\, phase 1.\nStudy: A Study to Investigate the Effect
 s of Impaired Hepatic Function on Velzatinib\nEstimated primary completion
 : 25 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/velz
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07859735
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218926-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Velzatinib: Phase 3 readout est. (NCT07218926)
DESCRIPTION:Velzatinib\, phase 3\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With
  Gastrointestinal Stromal Tumors After Imatinib Therapy\nEstimated primary
  completion: 30 May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/velzatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07218926
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843641-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Velzatinib: Phase 2 readout est. (NCT07843641)
DESCRIPTION:Velzatinib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
 \nEstimated primary completion: 31 January 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/velzatinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07843641
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585266-11196@assetmemo.bio
DTSTAMP:20261121T005727Z
DTSTART;VALUE=DATE:20320830
DTEND;VALUE=DATE:20320831
SUMMARY:Velzatinib: Phase 3 readout est. (NCT07585266)
DESCRIPTION:Velzatinib\, phase 3\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Study to Investigate Velzatinib Compared With Imatinib in Adult Particip
 ants With Previously Untreated Metastatic and/or Unresectable Gastrointest
 inal Stromal Tumors (StrateGIST Frontline)\nEstimated primary completion: 
 30 August 2032. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/velza
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07585266
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
